RA’s Role in Cross-Functional Digital Health and AI Governance Committees RA’s Role in Cross-Functional Digital Health and AI Governance Committees Context The integration of digital health technologies, particularly Software as a Medical Device (SaMD) and Artificial Intelligence (AI)-driven products, into healthcare systems is rapidly transforming patient care and pharmacovigilance practices. Regulatory Affairs (RA) professionals play a vital role in navigating the evolving landscape of regulation and compliance as these technologies mature. This article outlines the regulatory expectations and considerations for RA professionals involved in cross-functional governance committees overseeing digital health initiatives, with a focus on pharmacovigilance and emerging regulatory policy…

Integrating Digital Biomarkers and Mobile Health into Regulatory Strategies Integrating Digital Biomarkers and Mobile Health into Regulatory Strategies Context The regulatory landscape surrounding pharmaceuticals and biotechnological products is evolving rapidly, bolstered by advancements in digital health technologies such as digital biomarkers and mobile health (mHealth) applications. Regulatory Affairs (RA) professionals must stay informed about these trends, especially as they relate to pharmacovigilance (pharmacovig) frameworks. Digital tools are increasingly vital for monitoring safety and efficacy in real-world settings, presenting novel challenges and opportunities for regulatory compliance and strategy. Legal/Regulatory Basis In the EU, the regulatory environment is primarily governed by the…

Labeling, IFU and Transparency Requirements for AI-Enabled Products Labeling, IFU and Transparency Requirements for AI-Enabled Products As the integration of Artificial Intelligence (AI) technologies evolves within the healthcare landscape, regulatory expectations are concurrently developing to ensure patient safety and product efficacy. The regulatory frameworks imposed by agencies like the FDA, EMA, and MHRA emphasize stringent labeling, instructions for use (IFU), and transparency requirements for AI-enabled products. This article aims to provide an extensive overview of these regulatory expectations, particularly focusing on how Regulatory Affairs (RA) professionals can navigate the complexities surrounding AI-driven products. Context of Regulatory Affairs in AI-Enabled Products…

SaMD in Clinical Trials: ePRO, Digital Endpoints and Remote Monitoring SaMD in Clinical Trials: ePRO, Digital Endpoints and Remote Monitoring As the landscape of healthcare continues to evolve, the integration of technology in clinical trials, especially through Software as a Medical Device (SaMD), has garnered increasing focus within Regulatory Affairs (RA). This article aims to provide a comprehensive understanding of current regulations, guidelines, and agency expectations surrounding SaMD, specifically regarding electronic Patient-Reported Outcomes (ePRO), digital endpoints, and remote monitoring. Regulatory professionals can greatly benefit from this detailed manual as they navigate the complexities of emerging regulatory policies. Context SaMD refers…

Partnering with Tech Companies: Regulatory Risks and Contract Structures Partnering with Tech Companies: Regulatory Risks and Contract Structures Context The intersection of technology and healthcare is evolving rapidly, introducing a variety of opportunities and challenges in regulatory affairs. In an era where artificial intelligence (AI) is increasingly integrated into medical products, regulatory professionals in the pharmaceutical and biotech sectors are tasked with navigating a complex landscape of guidelines and expectations. This article serves as a comprehensive manual for regulatory affairs teams, particularly focusing on AI-driven digital health solutions and Software as a Medical Device (SaMD). Understanding the regulatory nuances of…

Designing Regulatory Roadmaps for Digital Companion Apps and Platforms Designing Regulatory Roadmaps for Digital Companion Apps and Platforms Context The rapid evolution of digital health technologies, particularly Digital Companion Apps and Software-as-a-Medical-Device (SaMD), presents a unique set of challenges and opportunities for Regulatory Affairs (RA) professionals. With the increasing reliance on pharmacovigilance systems, it has become imperative to develop well-structured regulatory roadmaps that align with evolving regulatory expectations across different jurisdictions, including the US, EU, and UK. Legal/Regulatory Basis In the context of digital health, the regulatory landscape is shaped by various guidelines and frameworks provided by major health authorities….

Using Sandboxes, Innovation Offices and Pilot Programs for Digital Health Using Sandboxes, Innovation Offices and Pilot Programs for Digital Health Context of Regulatory Affairs in Digital Health The rapid evolution of digital health technologies, such as Software as a Medical Device (SaMD) and AI-driven health solutions, has necessitated an adaptive regulatory framework. This framework aims to strike a balance between fostering innovation and ensuring patient safety. Regulatory authorities, including the FDA, EMA, and MHRA, are actively exploring novel approaches to regulation through the implementation of sandboxes, innovation offices, and pilot programs. These initiatives serve to enable developers and manufacturers to…

Future Policy Directions for AI, Big Data and Automation in Healthcare Future Policy Directions for AI, Big Data and Automation in Healthcare The rapid advancement of digital health technology, particularly Artificial Intelligence (AI), Big Data, and automation, is transforming the landscape of healthcare and pharmaceuticals. This transformation presents unique challenges and opportunities for Regulatory Affairs (RA) professionals tasked with ensuring compliance with evolving regulations. This article aims to provide an in-depth regulatory explainer manual focused on future policy directions for AI, Big Data, and automation in healthcare, specifically within the context of regulatory frameworks in the US, UK, and EU….

How RA Professionals Can Upskill for Digital and AI-Driven Products How RA Professionals Can Upskill for Digital and AI-Driven Products In an era where digital health technologies, software as a medical device (SaMD), and artificial intelligence (AI) are transforming the healthcare landscape, Regulatory Affairs (RA) professionals face the challenge of adapting to evolving regulations and expectations. This comprehensive guide explores the key regulatory frameworks, updates, and decision-making processes associated with digital health and AI-driven products, with a focus on navigating compliance within the US, UK, and EU regulatory environments. Regulatory Context With the rise of digital health innovations, RA professionals…

Balancing Innovation and Patient Protection in Digital Health Regulation Balancing Innovation and Patient Protection in Digital Health Regulation Digital health technology, including Software as a Medical Device (SaMD) and Artificial Intelligence (AI)-driven products, is shaping the future of healthcare. The rapid advancements in these areas promise improved patient outcomes but raise complex regulatory challenges. This article will provide a comprehensive regulatory explainer manual on the current expectations set by regulatory agencies in the US, UK, and EU regarding digital health technologies. Moreover, it will delve into relevant regulations, guidelines, documentation requirements, approval flows, and common deficiencies faced by industry stakeholders….